Extensively drug-resistant tuberculosis: an isolation order, public health powers, and a global crisis.

Through the quarantine looking glass: drug-resistant tuberculosis and public health governance, law, and ethics.

The incident in May-June 2007 involving a U.S. citizen traveling internationally while infected with drug-resistant tuberculosis involved the U.S. federal government's application of its quarantine and isolation powers. The incident and the isolation order raised numerous important issues for public health governance, law, and ethics. This article explores many of these issues by examining how ...

Control of Extensively Drug-Resistant Tuberculosis (XDR-TB): A Root Cause Analysis.

The threat of global infectious agents has the potential to cripple national and global economies, as the outbreaks of SARS, Avian Flu, H1N1, and XDR-TB have demonstrated. This article offers a Root Cause Analysis (RCA) of one public health case study - the Speaker case of XDR-TB - pinpointing the underlying causal relationships associated with this global health incident and proposing recommen...

The Involuntary Detention and Isolation of Patients Infected with Extreme Resistant Tuberculosis (xdr-tb): Implications for Public Health, Human Rights and Informed Consent

The emerging crisis of drug-resistant tuberculosis in South Africa: lessons from New York City.

Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis have emerged as important infections in South Africa among patients infected with human immunodeficiency virus (HIV). In the face of this new epidemic, South Africa must rededicate itself to the task of tuberculosis control and treatment with a rapid, multifaceted approach. Priorities include expansion of second-line t...

Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment

Multidrug-resistant tuberculosis (MDRTB), strains of Mycobacterium tuberculosis resistant to the first-line antituberculosis drugs rifampicin and isoniazid, is a global public health concern and remains a leading cause of mortality and morbidity in lowand middle-income countries [1]. In response, World Health Organization (WHO) member states have called for action to ‘‘achieve universal access ...